OPKO Health, Inc. Variable Lease, Cost
OPKO Health, Inc. (OPK) reported Variable Lease, Cost of $700.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-28
- OPKO Health, Inc. variable lease, cost for the quarter ending 2026-06-30 was $300.00K, a 0.00% change year-over-year.
- OPKO Health, Inc. variable lease, cost for the quarter ending 2026-03-31 was $400.00K, a 0.00% change year-over-year.
- OPKO Health, Inc. variable lease, cost for the quarter ending 2025-12-31 was $300.00K, a 25.00% decline year-over-year.
- OPKO Health, Inc. variable lease, cost for the quarter ending 2025-09-30 was $400.00K, a 20.00% decline year-over-year.
- OPKO Health, Inc. variable lease, cost for fiscal 2025 was $1.40M, a 26.32% decline from fiscal 2024.
- OPKO Health, Inc. variable lease, cost for fiscal 2024 was $1.90M, a 35.71% increase from fiscal 2023.
- OPKO Health, Inc. variable lease, cost for fiscal 2023 was $1.40M, a 46.15% decline from fiscal 2022.
- OPKO Health, Inc. variable lease, cost for fiscal 2022 was $2.60M, a 4.00% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 3 month as first filed | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $300.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $700.00K 10-Q/A · filed 2026-08-28 | $1.00M derived: sum of 3 quarters · filed 2026-08-28 | $1.40M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2026-03-31 | $400.00K 10-Q/A · filed 2026-08-28 | $700.00K derived: sum of 2 quarters · filed 2026-08-28 | $1.10M derived: sum of 3 quarters · filed 2026-08-28 | $1.40M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $700.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.00M derived: sum of 3 quarters · filed 2026-08-28 | $1.40M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $400.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2025-10-29 | $700.00K derived: sum of 2 quarters · filed 2026-08-28 | $1.10M 10-Q · filed 2025-10-29 | $1.50M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2025-06-30 | $300.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $700.00K 10-Q/A · filed 2026-08-28 | $1.10M derived: sum of 3 quarters · filed 2026-08-28 | $1.60M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2025-03-31 | $400.00K 10-Q/A · filed 2026-08-28 | $800.00K derived: sum of 2 quarters · filed 2026-08-28 | $1.30M derived: sum of 3 quarters · filed 2026-08-28 | $1.80M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2024-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $900.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.40M derived: sum of 3 quarters · filed 2026-02-26 | $1.90M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $1.00M derived: sum of 2 quarters · filed 2025-10-29 | $1.50M 10-Q · filed 2025-10-29 | $2.00M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $500.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $1.00M 10-Q · filed 2025-07-31 | $1.50M derived: sum of 3 quarters · filed 2026-02-26 | $1.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-01 | $1.00M derived: sum of 2 quarters · filed 2026-02-26 | $1.30M derived: sum of 3 quarters · filed 2026-02-26 | $1.20M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $800.00K derived: sum of 2 quarters · filed 2026-02-26 | $700.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.40M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $200.00K derived: sum of 2 quarters · filed 2024-11-07 | $900.00K 10-Q · filed 2024-11-07 | $1.50M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $600.00K 10-Q · filed 2024-08-07 | $1.20M derived: sum of 3 quarters · filed 2025-03-03 | $1.90M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $700.00K 10-Q · filed 2024-05-07 | $600.00K 10-Q · filed 2023-05-03 | $1.30M derived: sum of 2 quarters · filed 2025-03-03 | $2.00M derived: sum of 3 quarters · filed 2025-03-03 | $2.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $1.30M derived: sum of 2 quarters · filed 2025-03-03 | $2.20M derived: sum of 3 quarters · filed 2025-03-03 | $2.60M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.60M derived: sum of 2 quarters · filed 2023-11-06 | $2.00M 10-Q · filed 2023-11-06 | $3.10M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2022-06-30 | $900.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.30M 10-Q · filed 2023-08-03 | $2.40M derived: sum of 3 quarters · filed 2024-03-01 | $2.40M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-03 | $1.50M derived: sum of 2 quarters · filed 2024-03-01 | $1.50M derived: sum of 3 quarters · filed 2024-03-01 | $2.20M derived: sum of 4 quarters · filed 2024-03-01 | |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.10M derived: sum of 2 quarters · filed 2024-03-01 | $1.80M derived: sum of 3 quarters · filed 2024-03-01 | $2.50M 10-K · filed 2024-03-01 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $700.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.40M 10-Q · filed 2022-11-08 | $2.10M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.40M 10-Q · filed 2022-08-04 | $2.10M derived: sum of 3 quarters · filed 2023-02-27 | $2.80M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-03-31 | $700.00K 10-Q · filed 2022-05-09 | $1.40M derived: sum of 2 quarters · filed 2023-02-27 | $2.10M derived: sum of 3 quarters · filed 2023-02-27 | $2.90M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2020-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $1.40M derived: sum of 2 quarters · filed 2023-02-27 | $2.20M derived: sum of 3 quarters · filed 2023-02-27 | $3.00M 10-K · filed 2023-02-27 | |
| 2020-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $1.50M derived: sum of 2 quarters · filed 2021-10-28 | $2.30M 10-Q · filed 2021-10-28 | $3.10M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $1.60M 10-Q · filed 2021-07-29 | $2.40M derived: sum of 3 quarters · filed 2022-03-01 | $3.30M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $800.00K 10-Q · filed 2021-04-28 | $1.60M derived: sum of 2 quarters · filed 2022-03-01 | $2.50M derived: sum of 3 quarters · filed 2022-03-01 | $2.50M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.70M derived: sum of 2 quarters · filed 2022-03-01 | $1.70M derived: sum of 3 quarters · filed 2022-03-01 | $3.40M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $900.00K derived: sum of 2 quarters · filed 2020-10-29 | $2.60M 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $1.70M 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | $1.70M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |